Adagene: This study is assessing how safe and effective different dose levels of targeted therapy are in people with advanced and metastatic solid cancersA First-in-Human (FIH), Open-Label, Phase 1 Study of ADG206, a CD137 Agonist Antibody, in Subjects With Advanced/Metastatic Solid Tumors

Exclusion

• Subjects within washout period of other anti-tumor therapies. .
• History of prior malignancy other than the cancer under treatment in the study.
• Major trauma or major surgery within 4 weeks before the first dose of study drug.
• Serious nonhealing wound, ulcer, or bone fracture.
• History of significant immune-mediated AE.
• Central nervous system (CNS) disease involvement.
• Any evidence of underlying severe liver dysfunction.
• Prior organ allograft transplantations or allogeneic bone marrow, cord blood or peripheral blood stem cell transplantation.
• Clinically significant cardiac disease with insufficient cardiac function.
• Evidence of active uncontrolled viral, bacterial, or systemic fungal infection.
• Known positive test result for human immunodeficiency virus (HIV) or acquired immune deficiency syndrome (AIDS).
• Infection of hepatitis B virus (HBV), or hepatitis C virus (HCV) (unless the disease is clinically controlled) .
• History or risk of autoimmune disease.
• Subjects with active severe lung infection or with a history of interstitial lung diseases, noninfectious pneumonitis, active pulmonary tuberculosis, or evidence of active pneumonitis. Clinically significant and unmanageable ascites defined as requiring constant therapeutic paracentesis.
• Any serious underlying issue that would limit compliance with study requirements, impair the ability of the subject to understand informed consent.
• Known hypersensitivity, allergies, or intolerance to immunoglobulins or to any excipient contained in ADG206.
• Pregnant, lactating, or breastfeeding.